A boon for Cancer Patients

In recent years, cancer has shown an explosive trend, causing great trouble to people's normal life. With the rapid development of technology and medicine, a new cancer therapy technology has emerged - Nanoknife tumor ablation. By releasing high-voltage pulses on the tumor cell membrane, permanent nanoscale perforations are formed, disrupting the internal and external balance of the cell and causing rapid apoptosis. The domestically produced Nanoknife developed by Shanghai Yuanshan Medical Technology Co., Ltd. fills the gap of local innovative instruments and brings good news to cancer patients.

Health Strategy of The Two Sessions

On March 6, 2022, during the "Health Strategy of the Two Sessions" innovation session on the People's Daily client, three experts attended : Professor Tang Zhe from the Fourth Affiliated Hospital Zhejiang University School of Medicine(ZJU4H), Professor Xiao Yueyong from the First Medical Center of the PLA General Hospital, and Mr. Zhang Jianhao, Chairman of Shanghai Yuanshan Medical Technology Co., Ltd. They analyzed the original intention, accessibility, and application of domestically produced Nanoknife technology from multiple dimensions.

The livestreaming officially started at 7 pm and ended at 8 pm. Chairman Zhang Jianhao shared the development prospects of domestically produced medical devices from the industry perspective. The two experts introduced tumor and related therapy knowledge in detail, explaining the unique therapeutic technology of Nanoknife. As an innovative technology for cancer therapy, Nanoknife is gradually being promoted and recognized. Director Xiao particularly emphasized the domestically produced Nanoknife technology and products, which are not inferior to imported products in terms of progressiveness and maturity. During the one-hour livestreaming, netizens actively left messages, interacted, and liked the content, and the response was enthusiastic.

The Grand Occasion of Livestreaming 

During the livestreameing, the People's Daily Health Client and the People's Daily Health Times collaborated with multiple mainstream media platforms such as   Tencent News, Today's Headlines, Baidu Health, Sohu Video, Sina News, Sina Weibo, Yizhibo, Weibo Live, Zhihu, Kwai, Douyu, Huya to broadcast simultaneously. 

The total number of views for the livestreaming reached 1.874 million, and the feedback from netizens was enthusiastic. Among these platforms, the People's Daily Health Client had 293,000 views; Sohu Video had 392,000 views; Tencent News had 486,000 views and 50,000 interactions; the Health Times headline account, Health Times official Weibo live, Yizhibo, Kwai, Douyu, Huya and other platforms also had a high viewing volume of 703,000 and 50,000 likes.